Abnormal uterine bleeding is a common benign gynecological complaint and is also the most common symptom of endometrial cancer (EC). Although many microRNAs have been reported in endometrial carcinoma, most of them were identified from tumor tissues obtained at surgery or from cell lines cultured in laboratories. The objective of this study was to develop a method to detect EC-specific microRNA biomarkers from liquid biopsy samples to improve the early diagnosis of EC in women. Endometrial fluid samples were collected during patient-scheduled in-office visits or in the operating room prior to surgery using the same technique performed for saline infusion sonohysterography (SIS). The total RNA was extracted from the endometrial fluid specimens, followed by quantification, reverse transcription, and real-time PCR arrays. The study was conducted in two phases: exploratory phase I and validation phase II. In total, endometrial fluid samples from 82 patients were collected and processed, with 60 matched non-cancer versus endometrial carcinoma patients used in phase I and 22 in phase II. The 14 microRNA biomarkers, out of 84 miRNA candidates, with the greatest variation in expression from phase I, were selected to enter phase II validation and statistical analysis. Among them, three microRNAs had a consistent and substantial fold-change in upregulation (miR-429, miR-183-5p, and miR-146a-5p). Furthermore, four miRNAs (miR-378c, miR-4705, miR-1321, and miR-362-3p) were uniquely detected. This research elucidated the feasibility of the collection, quantification, and detection of miRNA from endometrial fluid with a minimally invasive procedure performed during a patient in-office visit. The screening of a larger set of clinical samples was necessary to validate these early detection biomarkers for endometrial cancer.

Objective—To compare calf weaning weight and associated economic variables for beef cows with serum antibodies against Mycobacterium avium subsp paratuberculosis (MAP) or from which MAP was isolated from feces with those for cows that were seronegative for antibodies against or culture negative for MAP. Design—Retrospective study. Animals—4,842 beef cows from 3 herds enrolled in the USDA National Johne's Disease Demonstration Herd Project. Procedures—Individual cow ELISA and culture results were obtained from the project database. During each parity evaluated for each cow, the 205-day adjusted weaning weight (AWW) of its calf was calculated. The AWW was compared between test-positive and test-negative cows by use of multilevel mixed-effect models. The median value for feeder calves from 2007 to 2011 was used to estimate the economic losses associated with MAP test–positive cows. Results—The AWW of calves from cows with strongly positive ELISA results was 21.48 kg (47.26 lb) less than that of calves from cows with negative ELISA results. The AWW of calves from cows classified as heavy or moderate MAP shedders was 58.51 kg (128.72 lb) and 40.81 kg (89.78 lb) less, respectively, than that of calves from MAP culture–negative cows. Associated economic losses were estimated as $57.49/calf for cows with strongly positive ELISA results and $156.60/calf and $109.23/calf for cows classified as heavy and moderate MAP shedders, respectively. Conclusions and Clinical Relevance—Calves from cows with MAP-positive test results had significantly lower AWWs than did calves from cows with MAP-negative test results, which translated into economic losses for MAP-infected beef herds.